Successful Artificial Intelligence led programme identifies multiple influenza drug targets
Successful Artificial Intelligence led programme identifies multiple influenza drug targets
Next-Generation Oral Vaccine Programme Advancing Through Non-Dilutive Funding
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company’s
Significant milestones reached, well capitalised and positioned for future growth
POLB 001 patent portfolio strengthened through granting of US patent
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza
Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications.
Early data readout indicates a successful LPS human challenge trial
Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme
Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases